Lee, Sung-Eun; Choi, Soo-Young; Kim, Soo-Hyun; Song, Hye-Young; Yoo, Hae-Lyun; Lee, Mi-Young; Hwang, Hee-Jeong; Kang, Ki-Hoon; Kee, Kyung-Mi; Jang, Eun-Jung; Kim, Dong-Wook
Leukemia & lymphoma
2017May ; 69 ( 5 ) :1-9.
PMID : 28540759
ÀúÀÚ »ó¼¼Á¤º¸
Lee, Sung-Eun -
Choi, Soo-Young -
Kim, Soo-Hyun -
Song, Hye-Young -
Yoo, Hae-Lyun -
Lee, Mi-Young -
Hwang, Hee-Jeong -
Kang, Ki-Hoon -
Kee, Kyung-Mi -
Jang, Eun-Jung -
Kim, Dong-Wook -
ABSTRACT
We conducted this study to identify the factors for predicting poor outcomes in chronic myeloid leukemia patients who failed to achieve a 3-month early molecular response (EMR). Of the 413 newly diagnosed, chronic phase, chronic myeloid leukemia patients receiving imatinib (IM), 120 (29.1%) failed to achieve a 3-month EMR. With a median follow-up of 67.0 months, 39 patients continued IM treatment with at least complete cytogenetic response (CCyR), and 81 patients permanently discontinued IM treatment. The cumulative incidence rates of CCyR and major molecular response (MMR) by 3 years were 90.1?±?3.9% and 53.7?±?7.3%, respectively. After adjusting for potential factors, multivariate analyses showed that a transcript type of e13a2, compared with e14a2, and a larger spleen size were independent factors for failure of overall MMR. The predictive factors outlined in this study may provide valuable information for high-risk patients who would benefit from early decision-making regarding therapy change.
Chronic myeloid leukemia, imatinib, early molecular response, transcript type, spleen size
¸µÅ©